Revelation Biosciences (NASDAQ:REVBW – Get Free Report) is anticipated to issue its results before the market opens on Thursday, November 5th. Analysts expect Revelation Biosciences to post earnings of ($6.16) per share for the quarter.
Revelation Biosciences Stock Performance
NASDAQ REVBW remained flat at $0.01 during trading hours on Tuesday. Revelation Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.04. The stock’s fifty day simple moving average is $0.01 and its 200 day simple moving average is $0.01.
About Revelation Biosciences
Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that harness the body’s innate immune system to prevent and treat disease. The company’s programs are based primarily on Gemini, its proprietary formulation of an innate immune modulator designed for administration through the nose.
Revelation’s product candidates are being investigated for potential use in respiratory and other infectious diseases, with research aimed at stimulating an early immune response in the nasal passages and airways.
Recommended Stories
- Five stocks we like better than Revelation Biosciences
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
- Check Point’s Turnaround Could Be Closer Than Investors Think
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
